aztreonam has been researched along with Antibiotic-Associated Colitis in 4 studies
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with vancomycin and aztreonam was associated with a rapid quantitative reduction in faecal colonisation with enterobacteriaceae, whereas there was no quantitative reduction in colonisation with enterobacteriaceae associated with treatment with vancomycin and gentamicin." | 2.67 | Enterobacteriaceae and neonatal necrotising enterocolitis. ( Langdale, V; Levene, M; MacKay, P; Martin, C; Millar, MR, 1992) |
| "We report on one rare case of recurrent pseudomembranous colitis associated with antibiotic treatment with Aztreonam." | 2.38 | [Antibiotic-associated pseudomembranous colitis--a case report with review of the literature]. ( Hegelmaier, C; Hütig, HB; Kalbheim, HJ, 1991) |
| "Aztreonam was the first compound to emerge that fulfilled the objectives of the program." | 1.27 | Aztreonam: the first monobactam. ( Bonner, DP; Sykes, RB, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Trifilio, SM | 1 |
| Pi, J | 1 |
| Mehta, J | 1 |
| Millar, MR | 1 |
| MacKay, P | 1 |
| Levene, M | 1 |
| Langdale, V | 1 |
| Martin, C | 1 |
| Hegelmaier, C | 1 |
| Hütig, HB | 1 |
| Kalbheim, HJ | 1 |
| Sykes, RB | 1 |
| Bonner, DP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II Study to Assess the Safety and Immunogenicity of WT1-A10 + AS01B Antigen-Specific Cancer Immunotherapeutic (ASCI) Combined With Infusions of ex Vivo Regulatory T Cells Depleted T Lymphocytes in in Vivo Regulatory T Cells Depleted Patients as [NCT01513109] | Phase 1/Phase 2 | 20 participants (Anticipated) | Interventional | 2011-12-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for aztreonam and Antibiotic-Associated Colitis
| Article | Year |
|---|---|
Changing epidemiology of Clostridium difficile-associated disease during stem cell transplantation.
Topics: Adult; Age Factors; Aged; Anti-Bacterial Agents; Aztreonam; Chicago; Ciprofloxacin; Clostridioides d | 2013 |
[Antibiotic-associated pseudomembranous colitis--a case report with review of the literature].
Topics: Adenocarcinoma; Aged; Aztreonam; Colostomy; Enterocolitis, Pseudomembranous; Female; Humans; Hystere | 1991 |
1 trial available for aztreonam and Antibiotic-Associated Colitis
| Article | Year |
|---|---|
Enterobacteriaceae and neonatal necrotising enterocolitis.
Topics: Aztreonam; Drug Therapy, Combination; England; Enterobacteriaceae Infections; Enterocolitis, Pseudom | 1992 |
1 other study available for aztreonam and Antibiotic-Associated Colitis
| Article | Year |
|---|---|
Aztreonam: the first monobactam.
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Bacterial Proteins; beta-Lactamases | 1985 |